Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Lüke

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|March 14, 2024
Editorial: Integrating transcriptional modulation in systemic tumor therapyDaniel Heudobler, Florian Lüke, Lina Ghibelli, et al.
International Journal of Molecular Sciences|January 28, 2026
Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic AcidDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Journal of Structural Biology|May 7, 2013
On the function of chitin synthase extracellular domains in biomineralizationIngrid M Weiss, Florian Lüke, Norbert Eichner, et al.
Frontiers in Pharmacology|April 4, 2025
MEPED as salvage therapy for relapsed/refractory Hodgkin's lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneckDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology|March 16, 2026
Editorial: Exploiting non-oncogene addiction for overcoming drug resistance in metastatic tumorsAlbrecht Reichle, Dennis Christoph Harrer, Florian Lüke, et al.
BMJ Open|October 21, 2025
Experts' attitudes towards 'targeted autopsies' using qualitative interviews in a medical network in GermanyUlrich Kaiser, Katja Evert, Ursula Vehling-Kaiser, et al.
Cancers|January 11, 2024
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell ResistanceDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology|March 12, 2026
Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasiasDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Oncology|January 26, 2024
Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticityDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology|June 21, 2021
Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced ChemotherapyFlorian Lüke, Dennis C Harrer, Joachim Hahn, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|March 14, 2024
Editorial: Integrating transcriptional modulation in systemic tumor therapyDaniel Heudobler, Florian Lüke, Lina Ghibelli, et al.
International Journal of Molecular Sciences|January 28, 2026
Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic AcidDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Journal of Structural Biology|May 7, 2013
On the function of chitin synthase extracellular domains in biomineralizationIngrid M Weiss, Florian Lüke, Norbert Eichner, et al.
Frontiers in Pharmacology|April 4, 2025
MEPED as salvage therapy for relapsed/refractory Hodgkin's lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneckDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology|March 16, 2026
Editorial: Exploiting non-oncogene addiction for overcoming drug resistance in metastatic tumorsAlbrecht Reichle, Dennis Christoph Harrer, Florian Lüke, et al.
BMJ Open|October 21, 2025
Experts' attitudes towards 'targeted autopsies' using qualitative interviews in a medical network in GermanyUlrich Kaiser, Katja Evert, Ursula Vehling-Kaiser, et al.
Cancers|January 11, 2024
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell ResistanceDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology|March 12, 2026
Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasiasDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Oncology|January 26, 2024
Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticityDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology|June 21, 2021
Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced ChemotherapyFlorian Lüke, Dennis C Harrer, Joachim Hahn, et al.
Pageof 4